This is a multi-national trial. The trial aims to study the long-term safety of LUM-201 in subjects with Idiopathic Pediatric Growth Hormone Deficiency (iPGHD). This study will also assess pharmacodynamics and efficacy response to therapy with LUM-201.

Start Date01 Aug 2023

Sponsor / Collaborator

Lumos Pharma, Inc.

NCT05364684 / Active, not recruitingPhase 2IIT

The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease: a Pilot Study

Nonalcoholic fatty liver disease (NAFLD), fatty infiltration of the liver in the absence of alcohol use, is an increasingly recognized complication of obesity, with prevalence estimates of about 30% of individuals in the United States. A subset of these will develop progressive disease in the form of nonalcoholic steatohepatitis (NASH), which can progress to cirrhosis and liver failure. The investigators hypothesize that LUM-201 (Ibutamoren mesylate) will decrease intrahepatic lipid accumulation as quantified by proton magnetic resonance spectroscopy (1H-MRS).

Start Date10 Aug 2022

Sponsor / Collaborator

The General Hospital Corp.

NCT05250063 / Active, not recruitingPhase 2

A Multicenter, Open-Label, Phase 2 Study to Evaluate Growth and Safety of LUM-201 Following 12 Months of Daily rhGH Treatment in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed the LUM-201-01 Trial

This is a multi-national trial. The goals of the trial are to study the growth response to LUM-201 administration in children with idiopathic growth hormone deficiency (GHD) previously treated with daily rhGH for 12 months in the LUM-201-01 trial.

Start Date18 Feb 2022

Sponsor / Collaborator

Lumos Pharma, Inc.

100 Clinical Results associated with Ibutamoren Mesylate

100 Translational Medicine associated with Ibutamoren Mesylate

100 Patents (Medical) associated with Ibutamoren Mesylate

102

Literatures (Medical) associated with Ibutamoren Mesylate

01 Jan 2025·BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Investigating the P53‐dependent anti‐cancer effect of ibutamoren in human cancer cell lines

Article

Author: Tanriverdi, Özgür ; Abdul Ghafoor, Naeem ; Yildiz, Ayşegül ; Rasuli, Sabina

Abstract:

The MDM2‐p53 pathway plays a pivotal role in regulating cell cycle and apoptosis, with its dysfunction contributing to approximately 50% of human malignancies. MDM2, an E3 ubiquitin ligase, targets the tumour suppressor p53 for degradation, thereby promoting uncontrolled cell growth in cancers. Inhibiting the MDM2‐p53 interaction represents a promising therapeutic strategy for reactivating p53’s tumour‐suppressive functions. This study explored the potential of ibutamoren (IBU) as a novel inhibitor of MDM2. In silico analyses utilizing molecular modelling revealed that IBU has a low IC50 for MDM2 inhibition and favourably binds to the p53‐binding pocket of MDM2. In vitro experiments demonstrated that IBU treatment reduced the viability of immortalized cancer cell lines with a functional MDM2‐p53 pathway but not in cell lines where this pathway harboured damaging mutations. This trend was further supported by RT‐qPCR analysis, which showed differential expression of two p53 target genes upon IBU treatment in cell lines with wild MDM2‐p53 pathways but not in those harbouring damaging mutations. These findings provide preliminary evidence supporting IBU's anticancer activity, plausibly through the MDM2‐p53 pathway, and suggest that further studies are warranted to explore its mechanism of action and potential development as a lead compound in oncology research.

24 Jul 2024·JCEM Case Reports

Reversible Gynecomastia and Hypogonadism Due to Usage of Commercial Performance-Enhancing Supplement Use

Article

Author: Koyyalamudi, Sundar R ; Perera, Nimalie J ; Chong, Serena ; Woolnough, Catherine A

Abstract:

Commercially available performance-enhancing supplements can contain banned performance-enhancing drugs (PEDs) and undisclosed steroid hormones that can induce hormonal abnormalities with associated clinical signs. We present a case of a 40-year-old male who developed bilateral gynecomastia and biochemical hypogonadotropic hypogonadism with a corresponding 6-month history of consuming commercially available performance-enhancing supplements for gym workouts. These performance-enhancing supplements were found to contain amounts of RAD-140, a selective androgen receptor modulator, MK-677, a GH secretagogue and cardarine, all of which are banned PEDs. In vitro analysis also detected undisclosed hormones testosterone, estradiol, and GH in all 3 supplements, with further steroid analysis using liquid chromatography mass spectrometry identifying an unidentified compound coeluting close to the testosterone peak. Cessation of these supplements led to full resolution of symptoms including normalization of hypogonadotropic hypogonadism. This case highlights the need for clinicians to consider commercially available performance-enhancing supplements as potential sources of PEDs and exogenous steroid hormones that can have adverse clinical consequences.

01 Mar 2023·Drug testing and analysis

Detection of the growth hormone secretagogue MK‐0677 in equine hair following oral administration

Article

Author: Habershon‐Butcher, Jocelyn ; Gray, Bob ; Viljanto, Marjaana ; Taylor, Polly ; Cutler, Charlotte

Abstract:

MK‐0677 (ibutamoren) is an orally active non‐peptide growth hormone secretagogue that binds to the ghrelin receptor stimulating the secretion of endogenous growth hormone. It is one of the most prevalent performance‐enhancing compounds currently available online and is potentially subject to abuse both in human and equine sports. The aim of the current study was to investigate whether it could be detected in equine hair following oral administration of MK‐0677 mesylate to a Thoroughbred racehorse. MK‐0677 and its O‐dealkylated metabolite were extracted using an existing method for prohibited substances in equine hair and analysed by liquid chromatography tandem mass spectrometry. This enabled the detection of MK‐0677 in all hair samples collected, up to 209 days in mane and 358 days in tail. A follow‐up methodology with an extensive wash procedure was carried out for selected hair samples, which unambiguously verified the presence of MK‐0677. Wash criteria to differentiate between internal incorporation (via bloodstream) and external deposition (via sweat and sebum) was also assessed and indicated internal incorporation for the samples collected at later time points (≥52 days) and a combination of internal incorporation and external deposition for hair samples collected at the earlier time point (2 days).

News (Medical) associated with Ibutamoren Mesylate

16 Dec 2024

·www.globenewswire.com

Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma

Dec. 12, 2024 -- Lumos Pharma, Inc. (NASDAQ:LUMO) (“Lumos Pharma” or the “Company”), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, and Double Point Ventures LLC (“DPV”) today announced the successful completion of the previously announced tender offer for Lumos Pharma’s shares at a purchase price of (i) $4.25 per share in cash at closing, without interest and less applicable tax withholding and (ii) one contingent value right (“CVR”) for each share of common stock outstanding, representing the future right to receive additional contingent cash payments upon the achievement of certain milestone events relating to the level of annual global net revenue of LUM-201 up to the year 2037, different transactions involving Lumos Pharma or its assets that occur within 18 months of closing or certain sales, license or similar revenue-generating agreements entered into within 18 months of closing and that are related to Lumos Pharma’s legacy products other than LUM-201. There can be no assurance any payments will be made with respect to the CVRs. The purchase price of $4.25 per share represents a total equity value of approximately $38 million, a premium of 7.6% to Lumos Pharma’s closing share price of $3.95 on October 22, 2024, and a premium of 10.5% to Lumos Pharma’s 30-trading-day volume weighted average price as of October 22, 2024. The tender offer expired one minute after 11:59pm Eastern Time on December 11, 2024. As of the expiration of the tender offer, 6,544,417 shares of Lumos Pharma common stock were validly tendered into and not withdrawn pursuant to the offer, representing approximately 75.62% of Lumos Pharma’s outstanding shares. All conditions of the tender offer were satisfied or waived and all shares validly tendered and not validly withdrawn were accepted for payment and DPV or its affiliates is promptly paying for all such tendered shares in accordance with the terms of the tender offer. As a result of its acceptance of the shares tendered in the tender offer, DPV and its affiliates acquired a sufficient number of shares of Lumos Pharma’s common stock to close the merger without the affirmative vote of Lumos Pharma’s other stockholders, pursuant to Section 251(h) of the Delaware General Corporation Law. As such, the merger was completed today, December 12, 2024. With the successful completion of the merger, Lumos Pharma will operate as a standalone business of DPV from its current headquarters in Austin, Texas. Each outstanding share of Lumos Pharma’s common stock that was not validly tendered in the tender offer (other than shares owned by affiliates of DPV, Lumos Pharma (as treasury stock) or by any stockholder of Lumos Pharma who is entitled to and properly demanded and perfected appraisal of such shares pursuant to, and complies in all respects with, the applicable provisions of Delaware law) was cancelled and converted into the right to receive (i) an amount in cash equal to $4.25 per share, without interest and less applicable tax withholding and (ii) one CVR. In addition, the common stock of Lumos Pharma ceased to trade on NASDAQ and a notice of delisting with respect to shares of Lumos Pharma is expected to be filed promptly by NASDAQ. Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~$4.7B global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/. Double Point Ventures is a venture capital fund dedicated to empowering healthcare and life sciences companies in developing groundbreaking drugs, medical devices, and diagnostics, with a mission to enhance patient outcomes and drive meaningful advancements in health. The content above comes from the network. if any infringement, please contact us to modify.

Orphan DrugAcquisition

21 Nov 2024

·www.globenewswire.com

Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action

AUSTIN, Texas, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials were presented orally at the 62nd Annual European Society for Paediatric Endocrinology Meeting, or ESPE 2024, held November 16-18, 2024 in Liverpool, UK. “The new analyses and updated data from our Phase 2 OraGrowtH210 and OraGrowtH212 Trials presented at ESPE this week demonstrate sustained growth on LUM-201 in moderate Pediatric Growth Hormone Deficiency (PGHD) to 24 months, as well as the correlation of LUM-201’s pulsatile mechanism of action (MOA) to growth,” said John C. McKew, PhD, President and Chief Scientific Officer of Lumos Pharma. “We are encouraged by these data and look forward to advancing oral LUM-201 in a Phase 3 clinical trial in moderate PGHD next year.” In the oral presentation of Abstract FC7.6 on Sunday, November 17th, entitled, Growth, IGF-1 and IGFBP-3 Responses to Oral LUM-201 in OraGrowtH210 and OraGrowtH212 Trials in Pediatric Growth Hormone Deficiency (PGHD) Over 12 to 24 Months on Treatment (Elżbieta Petriczko, MD, PhD, et al) [link], the investigator reviewed updated combined data from the Phase 2 OraGrowtH210 and OraGrowtH212 Trials out to 24 months following treatment with LUM-201. Results showed that at six months on LUM-201, a significant increase over baseline in Annualized Height Velocity (AHV) was observed for the combined 1.6 and 3.2 mg/kg/day doses. At baseline, AHV was 4.6 cm/yr for 37 subjects for which baseline data were available vs 7.8 cm/yr at 6 months on LUM-201 for 66 subjects.Results also showed that growth rates on oral LUM-201 (combined 1.6 and 3.2 mg/kg dose cohorts) were sustained out to 24 months with AHVs of 7.3 (N=65), 7.5 (N=36), and 7.3 (N=20) cm/yr at 12, 18, and 24 months, respectively [graphic below]. Combined results also demonstrated significant increases in IGF-1 and IGFBP-3 levels from baseline out to 24 months, with IGF-1 increasing from 13.1 (baseline) to 25.5 (12 months) to 29.2 (24 months) nmol/L and IGFBP-3 increasing from 133.5 (baseline) to 179.6 (12 months) to 186.2 (24 months) nmol/L.Conclusions: LUM-201 shows a significant increase in AHV at 6 months, and the effect continues with a minimal decrease in AHV through 24 months. Compared to historical rhGH (KIGS)1, LUM-201 has a smaller drop in AHV from 12 months to 24 months. LUM-201 significantly increases IGF-1 and IGFBP-3 levels at 12 months which continues to 24 months. A favorable investigational safety profile has been observed to date. In the late-breaking oral presentation of Abstract FC15.2 on Monday, November 18th, entitled, Amount and Pattern of Pulsatile GH Secretion Induced by the Oral Growth Hormone Secretagogue LUM-201 Is Related to Growth and IGF-1 Responses in Moderate Pediatric Growth Hormone Deficiency (PGHD) (Peter E. Clayton, MD, et al) [link], the investigator reviewed data from OraGrowtH212 demonstrating the relationship between pulsatile GH profiles and both the growth and IGF-1 responses to LUM-201 treatment. Data from 22 prepubertal children with moderate PGHD from the OraGrowtH212 Trial were evaluated with subjects grouped into tertiles based on 6-month annualized height velocity (AHV).Pulsatile growth hormone (GH) pulse assessments at baseline and at 6 months (M6) were characterized using 1) Approximate Entropy (ApEn, scale 0-1) examining degree of orderliness over the whole profile and 2) Functional Principal Component Analysis (FPCA) identifying where within the 12-hour profile, divided into 4-hour periods, the dominant variation occurred.Results of 6-month treatment with LUM-201: Pulsatile GH secretion, ApEn, IGF-1 SDS and IGFBP-3 SDS increased from baseline to M6.Greater M6 AHV was associated with an earlier periodicity of augmented pulsatile GH secretion [graphic below]. Conclusion: Both amount and pattern of GH secretion are important for growth and IGF-1 responses to LUM-201. 1 Ranke et al., 2010 – Pfizer KIGS database rhGH treated cohort of moderate prepubertal GHD children. About Lumos Pharma Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~$4.7B global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements of Lumos Pharma, Inc. that involve substantial risks and uncertainties. All such statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. A law that, in part, gives us the opportunity to share our outlook for the future without fear of litigation if it turns out our predictions were not correct. We are passionate about our business - including LUM-201 and the potential it may have to help patients in the clinic. This passion feeds our optimism that our efforts will be successful and bring about meaningful change for patients. Please keep in mind that actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. We have attempted to identify forward-looking statements by using words such as “projected,” “upcoming,” “will," “would,” “plan,” “intend,” “anticipate,” “approximate,” “expect,” “potential,” “imminent,” and similar references to future periods or the negative of these terms. Not all forward-looking statements contain these identifying words. Examples of forward-looking statements include, among others, statements we make regarding the advancement of oral LUM-201 to Phase 3, the potential for LUM-201 to be the first oral therapeutic for PGHD, and any other statements other than statements of historical fact. We wish we were able to predict the future with 100% accuracy, but that just is not possible. Our forward-looking statements are neither historical facts nor assurances of future performance. You should not rely on any of these forward-looking statements and, to help you make your own risk determinations, we have provided an extensive discussion of risks that could cause actual results to differ materially from our forward-looking statements including risks related to the timing and ability of Lumos Pharma to structure our Phase 3 trial in an effective and timely manner, the ability to initiate and advance a pivotal Phase 3 trial, as well as advance our clinical and corporate strategy in general, our ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the ability to successfully develop our product candidate, the effects of pandemics, other widespread health problems or military conflicts including the Ukraine-Russia conflict and the Middle East conflict and other risks that could cause actual results to differ materially from those matters expressed in or implied by such forward-looking statements including information in the "Risk Factors" section and elsewhere in Lumos Pharma’s Quarterly Report on Form 10-Q for the period ended September 30, 2024, as well as other subsequent reports filed with the SEC. All of these documents are available on our website. Before making any decisions concerning our stock, you should read and understand those documents. We anticipate that subsequent events and developments will cause our views to change. We may choose to update these forward-looking statements at some point in the future, however, we disclaim any obligation to do so. As a result, you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Investor & Media Contact: Lisa MillerLumos Pharma Investor Relations512-792-5454ir@lumos-pharma.com Photos accompanying this announcement are available athttps://www.globenewswire.com/NewsRoom/AttachmentNg/f1abdd2c-307b-47bb-8cc9-3c555fe00c85https://www.globenewswire.com/NewsRoom/AttachmentNg/b168603b-a009-4bce-a4d1-94367f1568ec Source: Lumos Pharma, Inc.

Clinical ResultPhase 2Orphan DrugPhase 1

30 Oct 2024

·www.globenewswire.com

Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62ⁿᵈ Annual ESPE Meeting 2024

AUSTIN, Texas, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that updated analyses of data from the Company’s Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for oral presentation at the 62nd Annual European Society for Paediatric Endocrinology Meeting, or ESPE 2024, to be held November 16-18, 2024 in Liverpool, UK. Two abstracts on data from the OraGrowtH Trials evaluating oral LUM-201 for Pediatric Growth Hormone Deficiency (PGHD) will be presented on Sunday, November 17th, by Elżbieta Petriczko, MD, PhD, Pomeranian Medical University, Szczecin, Poland, and on Monday, November 18th, by Peter E. Clayton, MD, University of Manchester, Manchester, UK, respectively. LUM-201 Oral Abstract Presentations: Sunday, November 17th – Session: Free Communications 7: GH and IGFs – 10:50AM Local Time FC7.6 Abstract entitled, Growth, IGF-1 and IGFBP-3 Responses to Oral LUM-201 in OraGrowtH210 and OraGrowtH212 Trials in Pediatric Growth Hormone Deficiency (PGHD) Over 12 to 24 Months on Treatment (Elżbieta Petriczko, MD, PhD, et al) Monday, November 18th – Session: Free Communications 15: Late Breaking – 9:40AM Local Time FC15.2 Abstract entitled, Amount and Pattern of Pulsatile GH Secretion Induced by the Oral Growth Hormone Secretagogue LUM-201 Is Related to Growth and IGF-1 Responses in Moderate Pediatric Growth Hormone Deficiency (PGHD) (Peter E. Clayton, MD, et al) About Lumos Pharma Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~$4.7B global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/. Investor & Media Contact: Lisa MillerLumos Pharma Investor Relations512-792-5454ir@lumos-pharma.com Source: Lumos Pharma, Inc.

Phase 2Orphan Drug

100 Deals associated with Ibutamoren Mesylate

External Link

KEGG	Wiki	ATC	Drug Bank
D04491	Ibutamoren Mesylate	-	-

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Fractures, Bone	Phase 3	US	Merck GmbH	-
Growth hormone deficiency	Phase 3	US	Merck GmbH	-
Osteoporosis, Postmenopausal	Phase 3	US	Merck GmbH	-
Nonalcoholic fatty liver	Phase 2	US	The General Hospital Corp.	10 Aug 2022
Nonalcoholic Steatohepatitis	Phase 2	US	The General Hospital Corp.	10 Aug 2022
Dwarfism, Pituitary	Phase 2	CL	Lumos Pharma, Inc.	01 Jun 2021
Chronic Kidney Diseases	Phase 2	US	Merck Sharp & Dohme Corp.	01 Mar 2009
Hip Fractures	Phase 2	DE	Merck Sharp & Dohme Corp.	01 Sep 2005
Hip Fractures	Phase 2	NO	Merck Sharp & Dohme Corp.	01 Sep 2005
Hip Fractures	Phase 2	ES	Merck Sharp & Dohme Corp.	01 Sep 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04614337 \| NCT04806854 (OraGrowtH212, Corporate Publications \| GlobeNewswire) Manual	Phase 2	Growth hormone deficiency	66	LUM-201	prtkljndhq(sikfftetgr) = tjsumvxlpa oimadclenf (jwovunizut ) View more	Positive	17 Nov 2024
ENDO2024	Phase 2	Growth hormone deficiency insulin-like growth factor-1 (IGF-1)	22	LUM-201 1.6 mg/kg/d	vbwzyskdgy(kgakkspgcw) = dzvfdnnqpw rixwerkxek (ehpbwreuws ) View more	Positive	01 Jun 2024
				LUM-201 3.2 mg/kg/d	vbwzyskdgy(kgakkspgcw) = grnqbvjvyw rixwerkxek (ehpbwreuws ) View more
NCT04614337 (OraGrowtH210, Corporate Publications) Manual	Phase 2	Growth hormone deficiency	-	LUM-201	qdmfmpgaon(uufqzlmyaf) = wokwekaymc jvttquljyt (atmfvdycrq ) Met View more	Positive	07 Nov 2023
OraGrowtH210 and OraGrowtH212 (ENDO2023)	Phase 2	Growth hormone deficiency insulin-like growth factor-1 (IGF-1)	-	LUM-201 1.6 mg/kg/day	ajxfdqmkrf(kyaugduriv) = bqfeuegihc pirymovaym (kswtpxnjil, 1.9)	Positive	05 Oct 2023
				LUM-201 3.2 mg/kg/day	ajxfdqmkrf(kyaugduriv) = bepvjvilmg pirymovaym (kswtpxnjil, 1.5)
OraGrowtH212 (ENDO2023)	Phase 2	Growth hormone deficiency IGF-1 \| GH	10	LUM-201 0.8 mg/kg	bmftahbipt(ykqtqpxrqc) = ibrjcochht gabjwcerqi (gpgkxtnnqa, + 10.6)	Positive	05 Oct 2023
				LUM-201 1.6 mg/kg	yibfdoqjhi(pvzmwduorg) = hnohpvogpr trcaagmbmy (gccjbondwm, + 0.65) View more
ESPE2023	Not Applicable	Growth hormone deficiency	15	LUM-201 1.6 mg/kg/day	bwmkubwxpj(dugfdwfkjl) = yrapjzsohp kqkfzftmnm (gqumucaqqx )	-	21 Sep 2023
				LUM-201 3.2 mg/kg/day	bwmkubwxpj(dugfdwfkjl) = tnpigibeaf kqkfzftmnm (gqumucaqqx )
NCT04806854 (OraGrowtH212, GlobeNewswire) Manual	Phase 2	Growth hormone deficiency	10	Ibutamoren Mesylate (1.6 mg/kg/day LUM-201)	lmmzjnhlua(eshilstqfh) = kultpikerl eayasaafbp (vfcfbgermc ) View more	Positive	14 Nov 2022
				Ibutamoren Mesylate (3.2 mg/kg/day LUM-201)	lmmzjnhlua(eshilstqfh) = iwinlmoogf eayasaafbp (vfcfbgermc ) View more
LUM-201 (ENDO2021)	Not Applicable	Growth hormone deficiency	68	LUM-201	gizixktvyv(hdwploolxh) = hrswaeyaxh fdsgquhmim (fnhzugobfa, 3.5 - 49)	Positive	03 May 2021
				Standard GH Secretagogues (clonidine, arginine, L-dopa, glucagon, insulin)	gizixktvyv(hdwploolxh) = gnxglsedbu fdsgquhmim (fnhzugobfa, 1.8 - 7.6)
NCT00395291 (Pubmed) Manual	Not Applicable	-	26	MK-0677	grapgwbwxw(hpffcecxze) = tgeyprswaz kbuedhpcrk (gzubdbpvnf, 1.48 - 2.10)	Positive	01 Mar 2018
				Placebo	grapgwbwxw(hpffcecxze) = gqsiszypmh kbuedhpcrk (gzubdbpvnf, 0.89 - 1.27)
NCT00395291 (CTgov)	Not Applicable	Kidney Failure, Chronic	49	MK-0677 (MK-0677)	fbqgxnqpua(muzdlliczo) = xfpyskynby saynqydsxd (yyrxlnoylh, ghgzcpqixn - yqtrnwfylo) View more	-	06 Jan 2012
				Placebo (Placebo)	fbqgxnqpua(muzdlliczo) = qnydkjdgxq saynqydsxd (yyrxlnoylh, bzfgvyzdok - avsffdvhuv) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis